Contrasting InfuSystem (INFU) and Its Competitors

InfuSystem (NYSE:INFUGet Rating) is one of 224 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its peers? We will compare InfuSystem to related businesses based on the strength of its valuation, profitability, dividends, institutional ownership, analyst recommendations, risk and earnings.

Analyst Ratings

This is a summary of current ratings and target prices for InfuSystem and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InfuSystem 0 0 0 0 N/A
InfuSystem Competitors 794 3301 7502 170 2.60

As a group, “Surgical & medical instruments” companies have a potential upside of 29.70%. Given InfuSystem’s peers higher probable upside, analysts clearly believe InfuSystem has less favorable growth aspects than its peers.

Volatility and Risk

InfuSystem has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, InfuSystem’s peers have a beta of 1.27, meaning that their average stock price is 27% more volatile than the S&P 500.

Valuation and Earnings

This table compares InfuSystem and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
InfuSystem $102.38 million $1.42 million 788.79
InfuSystem Competitors $1.07 billion $77.92 million 8.44

InfuSystem’s peers have higher revenue and earnings than InfuSystem. InfuSystem is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.


This table compares InfuSystem and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
InfuSystem 0.28% 0.63% 0.30%
InfuSystem Competitors -1,373.68% -130.99% -26.24%

Institutional and Insider Ownership

54.5% of InfuSystem shares are owned by institutional investors. Comparatively, 46.5% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 19.7% of InfuSystem shares are owned by company insiders. Comparatively, 14.2% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


InfuSystem beats its peers on 6 of the 10 factors compared.

InfuSystem Company Profile

(Get Rating)

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other alternate site settings comprising home care and home infusion providers, skilled nursing facilities, pain centers, hospital market, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

Receive News & Ratings for InfuSystem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InfuSystem and related companies with's FREE daily email newsletter.